ImmunityBio (NASDAQ:IBRX) Earns “Buy” Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $30.00 target price on the stock.

Separately, BTIG Research began coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $2.86 on Friday. ImmunityBio has a 1-year low of $2.28 and a 1-year high of $10.53. The business’s fifty day moving average price is $3.01 and its two-hundred day moving average price is $3.75. The company has a market capitalization of $1.99 billion, a P/E ratio of -3.11 and a beta of 0.94.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in the company. Stephens Inc. AR acquired a new position in shares of ImmunityBio during the 4th quarter valued at $26,000. Captrust Financial Advisors bought a new position in ImmunityBio during the third quarter valued at about $41,000. Cibc World Markets Corp acquired a new position in ImmunityBio during the fourth quarter worth about $35,000. Virtu Financial LLC bought a new stake in ImmunityBio in the third quarter worth about $51,000. Finally, Maia Wealth LLC bought a new stake in ImmunityBio in the fourth quarter worth about $37,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.